ATT 11T
Alternative Names: ATT-11T; Next generation irinotecan - Processa Pharmaceuticals; NGC-Irinotecan; PCS-11TLatest Information Update: 01 Nov 2024
Price :
$50 *
At a glance
- Originator Aposense
- Developer Aposense; Processa Pharmaceuticals; Teva Pharmaceutical Industries
- Class Antineoplastics; Camptothecins; Drug conjugates; Indolizines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA synthesis inhibitors; DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cervical cancer; Colorectal cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 30 Oct 2024 Processa Pharmaceuticals plans to initiate IND enabling studies and toxicology studies in 2025
- 19 Aug 2024 Pharmacodynamics data from preclinical studies in Cancer released by Processa Pharmaceuticals
- 28 Apr 2024 No recent reports of development identified for preclinical development in Solid-tumours in Israel (PO)